The following sections are included: <ul><li class="bullet">Introduction</li></ul> <ul><li class="bullet">Open Innovation in Turbulent Environments</li></ul> <ul><li class="bullet">Types of External Sources for Open Innovation in Turbulent Settings</li></ul> <ul><li class="bullet">Methods <ul><li class="bullet"> Data and sample</li><li class="bullet"> Measures <ul><li class="bullet"> Open innovation</li><li class="bullet"> Innovation success</li><li class="bullet"> Environmental turbulence</li><li class="bullet"> Controls</li></ul> <p></li><li class="bullet"> Results</li></ul> <p></li></ul> <ul><li class="bullet">Conclusion and...</li></ul></p></p>

This book investigates and highlights the most critical challenges the pharmaceutical industry faces in an increasingly competitive environment of inflationary R&D investments and tightening cost control pressures. The authors present three sources of pharmaceutical innovation: new management...

The pharmaceutical industry is exposed to severe conditions: while a typical R&D process lasts up to 13 years, only one out of 10,000 substances becomes a marketable product. In addition, markets for pharmaceutical products tend to become more fragmented, leading to an increased risk of market...

The pharmaceutical industry is in a dire situation: R&D still produces no more drugs than 10 years ago, while costs have quadrupled in the meantime. Little advances have been made in innovation efficiency. Worse yet, drug development times are unacceptably long, possible drug development targets...

This practical guide for advanced students and decision-makers in the pharma and biotech industry presents key success factors in RD along with value creators in pharmaceutical innovation. A team of editors and authors with extensive experience in academia and industry and at some of the most...